American Oriental Bioengineering, Inc. Common Stock Approved for Listing on the Archipelago Exchange
Friday November 11, 8:00 am ET
HONG KONG--(BUSINESS WIRE)--Nov. 11, 2005--American Oriental Bioengineering, Inc. (AMEX:AOB - News), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that its common stock has been approved for listing on the Archipelago Exchange (ArcaEx), a facility of the Pacific Exchange, under the symbol AOB. The Company anticipates that its common stock will commence trading on ArcaEx on November 11, 2005.
"We are pleased to bring this extra level of liquidity to our shareholders, and additional exposure to potential investors," said Tony (Shujun) Liu, the Company's Chief Executive Officer.
In addition to being listed on ArcaEx, the Company's common stock will continue to be listed on the American Stock Exchange under the symbol AOB.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. (AOBO) is a leading Chinese biotechnology company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. The Company also produces Cease-Enuresis Soft Gel, the only Chinese FDA-approved first grade, prescription medicine that is specially formulated to help alleviate bed-wetting and incontinence. The Company is a leading producer of products in both the nutriceuticals and pharmaceuticals areas in China. For more information, visit bioaobo.com. |
